FWIW, I'd say we're looking at about a .20 overshoot on news that was essentially expected. First off, a safety extension study, discounting the timeframe involved, might not be particularly all that large a scale to meet FDA (overkill requirements) so we'll wait for details on that front. Secondly, although PR sometimes lose something in the translation, sounds by the tone of it that the FDA actually is quite optimistic regarding the benefit that Hep represents to the patient population in need of it. Thirdly, next up, the EU.
I'm a buyer here in this range myself. I see value for sure at a discount.